All patients treated for Dupuytens disease at the Regional Hospital in Horsens from 2013 to 2016 with Clostridium histolyticum collagenase with a minimum of one year follow-up were reassessed in order to determine long-term outcomes. The improvement of motion and recurrence rate differed between the metacarpophalangeal (MCP) joints and the proximal interphalangeal joints, with much better results in MCP joints.
Read original article
Clostridium histolyticum as first-line treatment of Dupuytren’s disease
Charlotte Hartig-Andreasen, Lena Schroll & Jeppe Lange
All patients treated for Dupuytens disease at the Regional Hospital in Horsens from 2013 to 2016 with Clostridium histolyticum collagenase with a minimum of one year follow-up were reassessed in order to determine long-term outcomes.